{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:59:51Z","timestamp":1786993191823,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/05616-3"],"award-info":[{"award-number":["2018\/05616-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2019\/03429-4"],"award-info":[{"award-number":["2019\/03429-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/00351-4"],"award-info":[{"award-number":["2021\/00351-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/10292-5"],"award-info":[{"award-number":["2021\/10292-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jpba.2023.115635","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T16:14:36Z","timestamp":1691770476000},"page":"115635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS\/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women"],"prefix":"10.1016","volume":"235","author":[{"given":"Jhohann Richard de Lima","family":"Benzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Cristina","family":"Colombari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alef Machado Gomes","family":"Pego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Pereira","family":"dos Santos Melli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-6142","authenticated-orcid":false,"given":"Geraldo","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Lucia","family":"Lanchote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115635_bib1","doi-asserted-by":"crossref","first-page":"32939","DOI":"10.1021\/acsomega.0c03930","article-title":"Contribution of uptake and efflux transporters to oral pharmacokinetics of furosemide","volume":"5","author":"Chapa","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.jpba.2023.115635_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jacc.2018.10.075","article-title":"Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review","volume":"73","author":"Halpern","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jpba.2023.115635_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5262","article-title":"Development, validation, and implementation of an UHPLC\u2013MS\/MS method for the quantitation of furosemide in infant urine samples","volume":"36","author":"Vedar","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115635_bib4","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-022-00687-0","article-title":"State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references","volume":"24","author":"Bocci","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2023.115635_bib5","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1002\/jps.24489","article-title":"The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting - proposal of a four component transporter cocktail","volume":"104","author":"Ebner","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2023.115635_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020542","article-title":"Interplay of breast cancer resistance protein (Bcrp\/Abcg2), sex, and fed state in oral pharmacokinetic variability of furosemide in rats","volume":"15","author":"Sharma","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2023.115635_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2008.04.014","article-title":"In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway","volume":"76","author":"Kerdpin","year":"2008","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.jpba.2023.115635_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13318-017-0427-9","article-title":"Effects of metformin and furosemide on rosuvastatin pharmacokinetics in healthy volunteers: implications for their use as probe drugs in a transporter cocktail","volume":"43","author":"Stopfer","year":"2018","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"10.1016\/j.jpba.2023.115635_bib9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/bcp.13609","article-title":"Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug\u2013drug interactions","volume":"84","author":"Stopfer","year":"2018","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2023.115635_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2023.115635_bib11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cpt.1115","article-title":"Disease-associated changes in drug transporters may impact the pharmacokinetics and\/or toxicity of drugs: a white paper from the international transporter consortium","volume":"104","author":"Evers","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2023.115635_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0014-827X(00)00064-1","article-title":"High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies","volume":"55","author":"Abdel-Hamid","year":"2000","journal-title":"IL FARMACO"},{"key":"10.1016\/j.jpba.2023.115635_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-4347(98)00058-9","article-title":"High-performance liquid chromatographic determination of furosemide in plasma and urine and its use in bioavailability studies","volume":"710","author":"Abou-Auda","year":"1998","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115635_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/bmc.201","article-title":"Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-tandem mass spectrometry","volume":"16","author":"Deventer","year":"2002","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115635_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2116\/analsci.26.755","article-title":"Rapid UHPLC method for simultaneous determination of vancomycin, terbinafine, spironolactone, furosemide and their metabolites: application to human plasma and urine","volume":"26","author":"Baranowska","year":"2010","journal-title":"Anal. Sci."},{"key":"10.1016\/j.jpba.2023.115635_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cpt.406","article-title":"Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin","volume":"100","author":"Stopfer","year":"2016","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2023.115635_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jpba.2010.03.004","article-title":"Analytical issues in HPLC\/MS\/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples","volume":"52","author":"Sora","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115635_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-4347(94)00093-X","article-title":"Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection Preliminary pharmacokinetics and effect of probenecid","volume":"655","author":"Vree","year":"1994","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115635_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/jpet.118.252643","article-title":"Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects","volume":"368","author":"Shen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2023.115635_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/medicina58121780","article-title":"Impact of albumin binding function on pharmacokinetics and pharmacodynamics of furosemide","volume":"58","author":"Klinkmann","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.jpba.2023.115635_bib21","unstructured":"E. Medicines Agency, European Medicines Agency, Guideline on Bioanalytical Method Validation, 2011., (2011). chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/\u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf\u3009 (Accessed July 11, 2023)."},{"key":"10.1016\/j.jpba.2023.115635_bib22","unstructured":"FDA, Bioanalytical Method Validation Guidance for Industry, (2018). \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry\u3009 (Accessed 11 July 2023)."},{"key":"10.1016\/j.jpba.2023.115635_bib23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/phar.2800","article-title":"Renal function estimating equations performance during pregnancy and postpartum","volume":"43","author":"Zaghloul","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2023.115635_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpainsymman.2016.05.004","article-title":"Furosemide","volume":"52","author":"Carone","year":"2016","journal-title":"J. Pain. Symptom Manag."},{"key":"10.1016\/j.jpba.2023.115635_bib25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.pharep.2017.01.006","article-title":"Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions","volume":"69","author":"Kodati","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jpba.2023.115635_bib26","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/jcph.1681","article-title":"A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section","volume":"60","author":"Gon\u00e7alves","year":"2020","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2023.115635_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/FTD.0000000000000724","article-title":"Pregnancy alters CYP- and UGT-mediated metabolism of buprenorphine","volume":"42","author":"Zhang","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2023.115635_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics. A mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jpba.2023.115635_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.655320","article-title":"Pregnancy-related hormones increase UGT1A1-mediated labetalol metabolism in human hepatocytes","volume":"12","author":"Khatri","year":"2021","journal-title":"Front Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:35:03Z","timestamp":1760002503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523004041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":29,"alternative-id":["S0731708523004041"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115635","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS\/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115635"}}